Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Mosunetuzumab in Combination with Platinum-Based Salvage Chemotherapy for the Treatment of Relapsed/Refractory Aggressive B Cell Lymphoma

Trial Status: closed to accrual

This phase Ib trial studies the side effects and best dose of mosunetuzumab when given together with DHAX (dexamethasone, cytarabine, oxaliplatin) or ICE (ifosfamide, carboplatin, etoposide) in treating patients with aggressive B cell lymphoma that has come back (after a period of improvement) (relapsed) or that does not respond to treatment (refractory). Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as DHAX and ICE work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving mosunetuzumab and DHAX or ICE may work better in treating patients with relapsed or refractory aggressive B cell lymphoma.